|
Advertisement | |||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||
TABLE OF CONTENTS | |||||||||||||||||||||||||||||||||||||||||||||||
December 2017 Volume 16 Number 12 | Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||
| In this issue Comment News and Analysis Research Highlights Analysis Reviews
|
| |||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||
Comment: Legacy data sharing to improve drug safety assessment: the eTOX project Ferran Sanz, François Pognan, Thomas Steger-Hartmann, Carlos Díaz, Montserrat Cases, Manuel Pastor, Philippe Marc, Joerg Wichard, Katharine Briggs, David K. Watson, Thomas Kleinöder, Chihae Yang, Alexander Amberg, Maria Beaumont, Anthony J. Brookes, Søren Brunak, Mark T. D. Cronin, Gerhard F. Ecker, Sylvia Escher, Nigel Greene, Antonio Guzmán, Anne Hersey, Pascale Jacques, Lieve Lammens, Jordi Mestres, Wolfgang Muster, Helle Northeved, Marc Pinches, Javier Saiz, Nicolas Sajot, Alfonso Valencia, Johan van der Lei, Nico P. E. Vermeulen, Esther Vock, Gerhard Wolber & Ismael Zamora p811 | doi:10.1038/nrd.2017.177 The sharing of legacy preclinical safety data among pharmaceutical companies and its integration with other information sources offers unprecedented opportunities to improve the early assessment of drug safety. Here, we discuss the experience of the eTOX project, which was established through the Innovative Medicines Initiative to explore this possibility. Abstract | Full Text | PDF | Supplementary information | |||||||||||||||||||||||||||||||||||||||||||||||
NEWS AND ANALYSIS | Top | ||||||||||||||||||||||||||||||||||||||||||||||
Small molecules against RNA targets attract big backers Asher Mullard p813 | doi:10.1038/nrd.2017.239 Novartis, Merck, Pfizer and biotech entrepreneurs have started working on small-molecule drugs that act on an assortment of RNA targets, hoping to unlock once undruggable targets and new biology. | |||||||||||||||||||||||||||||||||||||||||||||||
Cryo-electron microscopy makes waves in pharma labs Mark Peplow p815 | doi:10.1038/nrd.2017.240 Companies hope the Nobel Prize-winning imaging methodology will reveal biomolecule characteristics that can guide drug discovery projects. | |||||||||||||||||||||||||||||||||||||||||||||||
NEWS IN BRIEF FDA approves first digital pill Asher Mullard p818 | doi:10.1038/nrd.2017.248 | |||||||||||||||||||||||||||||||||||||||||||||||
Second anticancer CAR T therapy receives FDA approval Asher Mullard p818 | doi:10.1038/nrd.2017.249 | |||||||||||||||||||||||||||||||||||||||||||||||
BTK inhibitors get a boost Asher Mullard p818 | doi:10.1038/nrd.2017.250 | |||||||||||||||||||||||||||||||||||||||||||||||
BIOBUSINESS BRIEFS Trial watch: Tracing investment in drug development for Alzheimer disease Alpha Tom Kodamullil, Firas Zekri, Meemansa Sood, Bastian Hengerer, Luc Canard, Duncan McHale & Martin Hofmann-Apitius p819 | doi:10.1038/nrd.2017.169 | |||||||||||||||||||||||||||||||||||||||||||||||
AN AUDIENCE WITH Eric Rubin p820 | doi:10.1038/nrd.2017.228 Eric Rubin, vice president of clinical oncology at Merck & Co, discusses tumour-agnostic approvals, immunotherapy combinations and the modernization of clinical trial eligibility criteria. | |||||||||||||||||||||||||||||||||||||||||||||||
FROM THE ANALYST'S COUCH The human microbiome: opportunity or hype? Pedro M. Valencia, Magali Richard, Jesse Brock & Elsy Boglioli p823 | doi:10.1038/nrd.2017.154 This article discusses investment in microbiome-based therapeutic approaches and key questions for the field related to the underlying science, clinical development, regulation and business models. | |||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||
ANALYSIS | Top | ||||||||||||||||||||||||||||||||||||||||||||||
Trends in GPCR drug discovery: new agents, targets and indications Alexander S. Hauser, Misty M. Attwood, Mathias Rask-Andersen, Helgi B. Schiöth & David E. Gloriam p829 | doi:10.1038/nrd.2017.178 G protein-coupled receptors (GPCRs) are the most intensively studied class of drug targets. This article presents a pioneering analysis of all GPCR-targeted drugs and agents that are currently in clinical trials, and discusses the trends across molecule types, drug targets and therapeutic indications. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||||||||||||
REVIEWS | Top | ||||||||||||||||||||||||||||||||||||||||||||||
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases Daniella M. Schwartz, Yuka Kanno, Alejandro Villarino, Michael Ward, Massimo Gadina & John J. O'Shea p843 | doi:10.1038/nrd.2017.201 Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines. Jakinibs — small-molecule inhibitors of JAKs — have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies. This Review discusses the biology, development and efficacy of jakinibs in the treatment of immune and inflammatory diseases. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||||||||||||
Tau-based therapies in neurodegeneration: opportunities and challenges Chuanzhou Li & Jurgen Gotz p863 | doi:10.1038/nrd.2017.155 Aggregates of the microtubule-associated protein tau are a defining feature of several neurodegenerative disorders, including Alzheimer disease (AD). Given the recent failures of several amyloid-β-targeted therapies for AD, interest is growing in tau as an alternative target, and this Review describes preclinical and clinical studies of tau-based approaches in the light of recent advances in the understanding of the physiological and pathological roles of tau. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||
|
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved. |
No comments:
Post a Comment